NEW YORK CITY (dpa-AFX) - Bristol-Myers Squibb Co. (BMY) said that the waiting period under the Hart-Scott-Rodino Antitrust Improvement Act of 1976, as amended for its tender offer for Inhibitex, Inc. (INHX) has expired. Bristol-Myers Squibb initiated on January 13, 2012, through its wholly-owned subsidiary Inta Acquisition Corp., a cash tender offer to purchase all outstanding shares of common stock of Inhibitex for $26.00 per share. The expiration of the HSR waiting period satisfies one of the conditions to the tender offer, which will expire at 12:00 midnight (New York City time) on Friday, February 10, 2012, unless extended in accordance with the merger agreement and the applicable rules and regulations of the SEC.
Copyright RTT News/dpa-AFX
© 2012 AFX News
